Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
Status:
Recruiting
Trial end date:
2036-10-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to access whether treatment of early state estrogen-rich breast
cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity
on lumpectomy specimen.